The use of 18F-FDG positron emission tomography to detect mediastinal lymph nodes in metastatic breast cancer

dc.contributor.authorOnal, Cem
dc.contributor.authorFindikcioglu, Alper
dc.contributor.authorGuler, Ozan Cem
dc.contributor.authorReyhan, Mehmet
dc.contributor.orcID0000-0001-6908-3412en_US
dc.contributor.orcID0000-0002-2742-9021en_US
dc.contributor.pubmedID33125983en_US
dc.contributor.researcherIDAAC-5654-2020en_US
dc.contributor.researcherIDD-5195-2014en_US
dc.date.accessioned2021-03-20T15:22:53Z
dc.date.available2021-03-20T15:22:53Z
dc.date.issued2020
dc.description.abstractBackground: To assess the predictive value of F-18-fluorodeoxyglucose positron-emission tomography (FDG-PET/CT) in detecting mediastinal lymph node metastasis with histopathologic verification in breast cancer (BC) patients. Materials and methods: Between February 2012 and October 2019, 37 BC patients who underwent histopathological verification for FDG-PET positive mediastinal lymph nodes were retrospectively analyzed. Nine patients (24%) were screened before beginning treatment, while 27 (76%) were screened at the time of disease progression, an average of 39 months after completion of initial treatment. Results: The histopathologic diagnosis revealed lymph node metastasis from BC in 15 patients (40%) and benign disease in 22 patients (60%). The standardized uptake value (SUVmax) of mediastinal lymph nodes was significantly higher in patients with lymph node metastasis compared to those with benign histology (9.0 +/- 3.5 vs. 5.9 +/- 2.4; P = 0.007). The cut-off value of SUVmax after the ROC curve analysis for pathological lymph node metastasis was 6.4. Two of the 15 patients with mediastinal SUVmax <= 6.4 and 13 of the 22 patients with SUVmax > 6.4 had lymph node metastasis. Age and pathological findings were prognostic factors for overall survival in univariate analysis. The treatment decision was changed in 19 patients (51%) after mediastinoscopic evaluation of the entire cohort. Conclusions: This is the first study to support the need for pathologic confirmation of a positive PET/CT result following evaluation of mediastinal lymph nodes for staging BC, either at initial diagnosis or at the time of progression. Treatment decisions were consequently altered for nearly half of the patients. (C) 2020 The Author(s). Published by Elsevier Ltd.en_US
dc.identifier.endpage202en_US
dc.identifier.issn0960-9776en_US
dc.identifier.scopus2-s2.0-85094628623en_US
dc.identifier.startpage197en_US
dc.identifier.urihttps://www.thebreastonline.com/article/S0960-9776(20)30202-2/pdf
dc.identifier.urihttp://hdl.handle.net/11727/5601
dc.identifier.volume54en_US
dc.identifier.wos000604437000030en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.breast.2020.10.011en_US
dc.relation.journalBREASTen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast canceren_US
dc.subjectFalse positivityen_US
dc.subjectLymph node metastasisen_US
dc.subjectMediastinal lymph nodeen_US
dc.subjectPositron emission tomographyen_US
dc.titleThe use of 18F-FDG positron emission tomography to detect mediastinal lymph nodes in metastatic breast canceren_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PIIS0960977620302022.pdf
Size:
745.56 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: